Browsing Tag
David Solomon
4 posts
Thalia Therapeutics (AIM: THAT) shares jump 17% as Sanmirna deal adds Phase 1 AML asset
Thalia Therapeutics has agreed to acquire Sanmirna Therapeutics and its Phase 1 acute myeloid leukaemia drug miRisten, while raising £2.75 million to fund clinical data expected in 2027.
Goldman just posted its second-best quarter ever. Here’s what it means for GS investors in 2026
Goldman Sachs (NYSE: GS) beat Q1 2026 earnings with USD 17.55 EPS and USD 17.23B revenue. What record equities trading and a 48% IB fee surge mean for investors.
Goldman Sachs smashes Q1 estimates with $4.74bn profit as equities, FICC deals surge
Goldman Sachs delivered $4.74B in Q1 profit with strong earnings from equities, FICC, and debt underwriting. Find out what drove the gains this quarter.
Goldman Sachs delivers robust 2024 earnings with record growth in key segments
Goldman Sachs Group, Inc. (NYSE: GS) showcased an impressive financial performance for 2024, reporting net revenues of $53.51…